Q2 2014

Source filing unavailable

Q2 2014 · —

Revenue

$5.30M

−5.4% vs Q2 2013

Net Income

$1.23M

no prior Q2 2013 on file

EPS, diluted—

Operating Income$1,378,000N/M

Operating Cash Flowderived-$2,225,000—

Free Cash Flowderived

Same quarter

Metric	Q2 2014	Q2 2013
Revenue	$5.30M	$5.60M
Net Income	$1.23M	—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR